167 related articles for article (PubMed ID: 37317655)
21. Bile Acids Signal via TGR5 to Activate Intestinal Stem Cells and Epithelial Regeneration.
Sorrentino G; Perino A; Yildiz E; El Alam G; Bou Sleiman M; Gioiello A; Pellicciari R; Schoonjans K
Gastroenterology; 2020 Sep; 159(3):956-968.e8. PubMed ID: 32485177
[TBL] [Abstract][Full Text] [Related]
22. Gut microbiota-related bile acid metabolism-FXR/TGR5 axis impacts the response to anti-α4β7-integrin therapy in humanized mice with colitis.
Han B; Lv X; Liu G; Li S; Fan J; Chen L; Huang Z; Lin G; Xu X; Huang Z; Zhan L; Lv X
Gut Microbes; 2023; 15(1):2232143. PubMed ID: 37431863
[TBL] [Abstract][Full Text] [Related]
23. Jiang-Tang-San-Huang pill alleviates type 2 diabetes mellitus through modulating the gut microbiota and bile acids metabolism.
Tawulie D; Jin L; Shang X; Li Y; Sun L; Xie H; Zhao J; Liao J; Zhu Z; Cui H; Wen W
Phytomedicine; 2023 May; 113():154733. PubMed ID: 36870307
[TBL] [Abstract][Full Text] [Related]
24. Bile acids contribute to the development of non-alcoholic steatohepatitis in mice.
Gillard J; Clerbaux LA; Nachit M; Sempoux C; Staels B; Bindels LB; Tailleux A; Leclercq IA
JHEP Rep; 2022 Jan; 4(1):100387. PubMed ID: 34825156
[TBL] [Abstract][Full Text] [Related]
25. Hyodeoxycholic acid (HDCA) suppresses intestinal epithelial cell proliferation through FXR-PI3K/AKT pathway, accompanied by alteration of bile acids metabolism profiles induced by gut bacteria.
Song M; Yang Q; Zhang F; Chen L; Su H; Yang X; He H; Liu F; Zheng J; Ling M; Lai X; Zhu X; Wang L; Gao P; Shu G; Jiang Q; Wang S
FASEB J; 2020 May; 34(5):7103-7117. PubMed ID: 32246800
[TBL] [Abstract][Full Text] [Related]
26. Bile acid treatment and FXR agonism lower postprandial lipemia in mice.
Farr S; Stankovic B; Hoffman S; Masoudpoor H; Baker C; Taher J; Dean AE; Anakk S; Adeli K
Am J Physiol Gastrointest Liver Physiol; 2020 Apr; 318(4):G682-G693. PubMed ID: 32003602
[TBL] [Abstract][Full Text] [Related]
27. Bisphenol A induced hepatic steatosis by disturbing bile acid metabolism and FXR/TGR5 signaling pathways via remodeling the gut microbiota in CD-1 mice.
Hong T; Zou J; He Y; Zhang H; Liu H; Mai H; Yang J; Cao Z; Chen X; Yao J; Feng D
Sci Total Environ; 2023 Sep; 889():164307. PubMed ID: 37211107
[TBL] [Abstract][Full Text] [Related]
28. Hepatic Bile Acid Reuptake in the Rat Depends on Bile Acid Conjugation but Not on Agonistic Properties towards FXR and TGR5.
Trammell SAJ; Svenningsen JS; Holst JJ; Gillum MP; Kuhre RE
Molecules; 2020 May; 25(10):. PubMed ID: 32443832
[TBL] [Abstract][Full Text] [Related]
29. Farnesoid X receptor induces Takeda G-protein receptor 5 cross-talk to regulate bile acid synthesis and hepatic metabolism.
Pathak P; Liu H; Boehme S; Xie C; Krausz KW; Gonzalez F; Chiang JYL
J Biol Chem; 2017 Jun; 292(26):11055-11069. PubMed ID: 28478385
[TBL] [Abstract][Full Text] [Related]
30. The double-edged sword of probiotic supplementation on gut microbiota structure in
Nabavi-Rad A; Sadeghi A; Asadzadeh Aghdaei H; Yadegar A; Smith SM; Zali MR
Gut Microbes; 2022; 14(1):2108655. PubMed ID: 35951774
[TBL] [Abstract][Full Text] [Related]
31. Atorvastatin protects against liver and vascular damage in a model of diet induced steatohepatitis by resetting FXR and GPBAR1 signaling.
Marchianò S; Biagioli M; Roselli R; Zampella A; Di Giorgio C; Bordoni M; Bellini R; Morretta E; Monti MC; Distrutti E; Fiorucci S
FASEB J; 2022 Jan; 36(1):e22060. PubMed ID: 34862975
[TBL] [Abstract][Full Text] [Related]
32. The Gut Microbiota as a Therapeutic Target in IBD and Metabolic Disease: A Role for the Bile Acid Receptors FXR and TGR5.
Baars A; Oosting A; Knol J; Garssen J; van Bergenhenegouwen J
Microorganisms; 2015 Oct; 3(4):641-66. PubMed ID: 27682110
[TBL] [Abstract][Full Text] [Related]
33. Investigation on bile acid receptor regulators. Discovery of cholanoic acid derivatives with dual G-protein coupled bile acid receptor 1 (GPBAR1) antagonistic and farnesoid X receptor (FXR) modulatory activity.
Sepe V; Renga B; Festa C; Finamore C; Masullo D; Carino A; Cipriani S; Distrutti E; Fiorucci S; Zampella A
Steroids; 2016 Jan; 105():59-67. PubMed ID: 26607331
[TBL] [Abstract][Full Text] [Related]
34. Interaction of gut microbiota with dysregulation of bile acids in the pathogenesis of nonalcoholic fatty liver disease and potential therapeutic implications of probiotics.
Chen J; Thomsen M; Vitetta L
J Cell Biochem; 2019 Mar; 120(3):2713-2720. PubMed ID: 30443932
[TBL] [Abstract][Full Text] [Related]
35. Intestinal bile acid receptors are key regulators of glucose homeostasis.
Trabelsi MS; Lestavel S; Staels B; Collet X
Proc Nutr Soc; 2017 Aug; 76(3):192-202. PubMed ID: 27846919
[TBL] [Abstract][Full Text] [Related]
36. Bile acid coordinates microbiota homeostasis and systemic immunometabolism in cardiometabolic diseases.
Guan B; Tong J; Hao H; Yang Z; Chen K; Xu H; Wang A
Acta Pharm Sin B; 2022 May; 12(5):2129-2149. PubMed ID: 35646540
[TBL] [Abstract][Full Text] [Related]
37. Immunomodulatory functions of FXR.
Fiorucci S; Zampella A; Ricci P; Distrutti E; Biagioli M
Mol Cell Endocrinol; 2022 Jul; 551():111650. PubMed ID: 35472625
[TBL] [Abstract][Full Text] [Related]
38. Intestinal crosstalk between bile acids and microbiota in irritable bowel syndrome.
Deng X; Xiao L; Luo M; Xie P; Xiong L
J Gastroenterol Hepatol; 2023 Jul; 38(7):1072-1082. PubMed ID: 36869260
[TBL] [Abstract][Full Text] [Related]
39. Intestinal Farnesoid X Receptor and Takeda G Protein Couple Receptor 5 Signaling in Metabolic Regulation.
Chiang JY; Pathak P; Liu H; Donepudi A; Ferrell J; Boehme S
Dig Dis; 2017; 35(3):241-245. PubMed ID: 28249273
[TBL] [Abstract][Full Text] [Related]
40. Interactions between bile salts, gut microbiota, and hepatic innate immunity.
Schubert K; Olde Damink SWM; von Bergen M; Schaap FG
Immunol Rev; 2017 Sep; 279(1):23-35. PubMed ID: 28856736
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
